The association between fatty liver index and microalbuminuria in middle-aged and elderly population in Shanghai

doi:10.16150/j.1671-2870.2020.06.011

Abstract

Abstract:

Objective: To investigate the association between fatty liver index (FLI) and prevalence of microalbuminuria. Methods: A cross-sectional survey of 4 012 subjects aged 40 years or older in Songnan Community, Shanghai was conducted in 2009. Questionnaire and anthropometric measurements were collected, and microalbuminuria and the FLI were determined. The association between FLI and microalbuminuria was analyzed. Results: Among the 3 415 subjects in the current analysis, the prevalence of microalbuminuria increased with increase of the FLI. The corresponding prevalence of microalbuminuria were 6.86%, 10.99% and 15.28% in low FLI group(FLI<30), intermediate FLI group(30≤FLI<60) and the high FLI group(FLI≥60), respectively (P<0.000 1). After adjustment for age, sex, smoking status, current drinking, physical activity, systolic blood pressure, diabetes and total cholesterol, the high FLI group was associated with 58% increased risk of microalbuminuria compared with the low FLI group (OR=1.58, 95% CI 1.17-2.15, P=0.003 2). In the same adjusting model,the risk in prevalence of microalbuminuria increased 10% for each 10 unit increase in FLI (OR=1.10, 95% CI 1.04-1.15, P=0.000 2). Conclusions: FLI increas is associated with increased risk of microalbuminuria in subjects aged 40 years or older in Songnan Community, Shanghai.

Key words: Fatty liver index, Microalbuminuria, Metabolic disorders

CLC Number:

R575.5

ZUO Guangmin, PENG Kui, LI Mian, XU Min, BI Yufang, NING Guang. The association between fatty liver index and microalbuminuria in middle-aged and elderly population in Shanghai[J]. Journal of Diagnostics Concepts & Practice, 2020, 19(06): 605-609.

Figures/Tables 6

References 13

[1]	Byrne CD, Targher G. NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl):S47-S64.
[2]	Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009, 50(1):204-210. doi: 10.1016/j.jhep.2008.10.010 URL
[3]	Armstrong MJ, Adams LA, Canbay A,etal. Extrahepatic complications of nonalcoholic fatty liver disease[J]. Hepa-tology, 2014, 59(3):1174-1197.
[4]	Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population[J]. BMC Gastroenterol, 2006, 6:33. doi: 10.1186/1471-230X-6-33 URL
[5]	Huang X, Xu M, Chen Y, et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly chinese[J]. Medicine (Baltimore), 2015, 94(40):e1682. doi: 10.1097/MD.0000000000001682 URL
[6]	Hwang ST, Cho YK, Yun JW, et al. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes[J]. Intern Med J, 2010, 40(6):437-442. doi: 10.1111/j.1445-5994.2009.01979.x pmid: 19460054
[7]	Kasapoglu B, Turkay C, Yalcın KS, et al. Increased microalbuminuria prevalence among patients with nonalcoholic fatty liver disease[J]. Ren Fail, 2016, 38(1):15-19. doi: 10.3109/0886022X.2015.1106845 pmid: 26540639
[8]	Kim BJ, Kim BS, Kang JH. The association between serum ferritin level, microalbuminuria and non-alcoholic fatty liver disease in non-diabetic, non-hypertensive men[J]. Clin Exp Hypertens, 2014, 36(6):380-385. doi: 10.3109/10641963.2013.827704 URL
[9]	Pedrinelli R, Penno G, Dell'Omo G, et al. Microalbumi-nuria and transcapillary albumin leakage in essential hypertension[J]. Hypertension, 1999, 34(3):491-495. pmid: 10489399
[10]	Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(6):330-344. doi: 10.1038/nrgastro.2013.41 URL
[11]	Parvanova AI, Trevisan R, Iliev IP, et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and diffe-rent degrees of urinary albumin excretion[J]. Diabetes, 2006, 55(5):1456-1462. pmid: 16644705
[12]	郝明丽, 徐敏. 代谢组学在2型糖尿病研究中的应用及进展[J]. 内科理论与实践, 2016, 11(3):191-194.
[13]	林安华, 王晨秀, 霍亚南, 等. 社区糖尿病患者血压水平与慢性肾脏疾病及其进展的相关性研究[J]. 诊断学理论与实践, 2017, 16(2):178-182.

变量	FLI<30	30≤FLI<60	FLI≥60	P值
人数[例（n）]	1 603(46.9%)	1 092(32.0%)	720(21.1%)
年龄（岁）	59.5±10.0	62.3±9.7	62.1±9.9	<0.000 1
体质量指数（kg/m²）	22.4±2.5	25.8±2.2	29.0±3.5	<0.000 1
腰围（cm）	80.1±6.9	89.8±5.9	98.2±8.0	<0.000 1
吸烟状态[例（n）]	213(13.3%)	184(16.9%)	137(19.0%)	<0.050 0
饮酒状态[例（n）]	130(8.1%)	98(9.0%)	61(8.5%)	0.730 0
体力活动[例（n）]				<0.000 1
低	1 047(65.3%)	772(70.7%)	536 (74.4%)
中等	412(25.7%)	247(22.6%)	151 (21.0%)
高	144(9.0%)	73(6.7%)	33 (4.6%)
收缩压（mmHg）	132±21	142±21	147±22	<0.000 1
舒张压（mmHg）	76±10	79±10	82±10	<0.000 1
总胆固醇（mmol/L）	5.0±0.9	5.2±1.0	5.4±1.0	<0.000 1
高密度脂蛋白胆固醇（mmol/L）	1.4±0.3	1.3±0.3	1.3±0.2	<0.000 1
低密度脂蛋白胆固醇（mmol/L）	2.3±0.6	2.5±0.7	2.5±0.8	<0.000 1
三酰甘油（mmol/L）	1.1(0.8~1.4)	1.7(1.3~2.3)	2.3(1.7~3.3)	<0.000 1
GOT（u/L）	20(17~23)	21(18~25)	24(19~32)	<0.000 1
GPT（u/L）	15(12~21)	21(14~28)	27(19~41)	<0.000 1
γ-GGT（u/L）	18(14~24)	25(19~35)	38(26~57)	<0.000 1
空腹血糖（mmol/L）	5.0(4.6~5.6)	5.3(4.8~6.2)	5.8(5.1~7.3)	<0.000 1
餐后血糖（mmol/L）	6.8(5.6~9.1)	8.7(6.8~13.6)	11.2(7.7~16.5)	<0.000 1
糖化血红蛋白（%）	6.0(5.7~6.4)	6.2(5.9~6.9)	6.7(6.1~7.7)	<0.000 1
HOMA-IR	1.2(0.8~1.8)	2.1(1.4~3.0)	3.3(2.3~5.0)	<0.000 1
尿白蛋白/肌酐比值	4.9(2.5~10.1)	6.2(2.9~13.1)	7.9(3.4~18.3)	<0.000 1
估算肾小球滤过率[mL/（min·1.73 m²）]	114.0±46.6	110.3±23.8	108.5±27.1	<0.050 0
高血压	572(35.7%)	619(56.7%)	461(64.0%)	<0.000 1
糖尿病	335(21.0%)	405(37.1%)	378(52.5%)	<0.000 1

校正模型	OR（95%CI）
校正模型	模型 1	模型 2	模型 3
FLI/10	1.17(1.12~1.22)	1.16(1.11~1.21)	1.10(1.04~1.15)
P值	<0.000 1	<0.000 1	0.000 2
FLI<30	1.00	1.00	1.00
30≤FLI<60	1.68(1.28~2.20)	1.55(1.18~2.04)	1.25(0.94~1.67)
FLI≥60	2.45(1.85~3.24)	2.27(1.71~3.01)	1.58(1.17~2.15)
P值	<0.000 1	<0.000 1	0.003 2